SPDR S&P Biotech ETF
$XBI · State Street · tracks S&P Biotechnology Select Industry Index · since 2006
Dividend yield
0.14%
Expense ratio
0.35%
Assets
$7.4B
About XBI
Tracks the S&P Biotechnology Select Industry Index using an equal-weight methodology, giving smaller biotech companies comparable influence to large-caps like Amgen. XBI is the most widely traded biotech ETF, popular with traders and investors seeking diversified biotech exposure.
Top holdings
Sector exposure
- Clinical Stage Biotech42.4%
- Commercial Stage Biotech36.8%
- Large-Cap Biotech12.6%
- Other8.2%
How StockWorthy analyses XBI
ETFs hold companies rather than generating cash flow themselves, so XBI is assessed on cost, income and the valuation of what it owns: the expense ratio, the current yield against its own 0.12% long-run average, and a holdings-weighted P/E and growth rate built from the underlying positions. Figures are educational and not investment advice.
Sign in to see live pricing, yield history and the full holdings breakdown, or browse all ETFs.